Related Experiment Video
Updated: Jan 11, 2026
07:08
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
1.3K
Advancing Cancer Biology: Highlights from the 2025 FASEB SRC on Cellular Plasticity in Cancer
Hans Clevers1, Ankur Sharma2, Sendurai A Mani3,4
1Pharma, Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Cancer Heterogeneity and Plasticity
|November 12, 2025
Summary
This conference highlighted cancer cell plasticity research, covering reprogramming, metastasis, and therapeutic strategies. Insights aim to advance cancer biology and treatment.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Cancer cell plasticity is crucial for tumor development, progression, and metastasis.
- Understanding these dynamic cellular states is key to developing effective cancer therapies.
Purpose of the Study:
- To convene experts discussing the latest research on cancer cell plasticity.
- To explore mechanisms, implications, and therapeutic targeting of cancer cell plasticity.
Main Methods:
- The conference featured presentations from leading researchers in the field.
- Discussions covered a wide range of topics related to cancer cell plasticity.
Main Results:
- Comprehensive overview of oncofetal reprogramming, metabolic reprogramming, and metastasis in cancer.
- Exploration of cancer stem cell programs, tumor microenvironment interactions, and immune evasion.
- Discussion of novel therapeutic strategies targeting cancer cell states and stem-like properties.
Conclusions:
- The conference provided a platform for sharing cutting-edge advancements in cancer cell plasticity.
- The insights generated are expected to drive future progress in cancer biology and therapeutic interventions.
Keywords:
cancer cell plasticitycancer stem cellscellular plasticityimmune evasionphenotypic switchingtherapy resistancetumor microenvironmentMore Related Videos
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
02:40Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
03:03mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
01:29Somatic to iPS Cell Reprogramming
2.6K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.6K
01:22iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K